Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act.

Nipp RD, Shui AM, Perez GK, Kirchhoff AC, Peppercorn JM, Moy B, Kuhlthau K, Park ER.

JAMA Oncol. 2018 Mar 29. doi: 10.1001/jamaoncol.2018.0097. [Epub ahead of print]

PMID:
29596618
2.

Intravascular Cooling Catheter-Related Venous Thromboembolism After Hypothermia: A Case Report and Review of the Literature.

Wang X, Moy BT, Hiendlmayr BJ, Krainski F, Duvall WL, Fernandez AB.

Ther Hypothermia Temp Manag. 2018 Mar 23. doi: 10.1089/ther.2017.0059. [Epub ahead of print]

PMID:
29570428
3.

AR Expression in Breast Cancer CTCs Associates with Bone Metastases.

Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S.

Mol Cancer Res. 2018 Apr;16(4):720-727. doi: 10.1158/1541-7786.MCR-17-0480. Epub 2018 Feb 16.

PMID:
29453314
4.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.

PMID:
29146401
5.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B.

J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16.

PMID:
29035643
6.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.

Van Poznak C, Somerfield MR, Moy B.

J Oncol Pract. 2017 Dec;13(12):822-824. doi: 10.1200/JOP.2017.027672. Epub 2017 Oct 16. No abstract available.

PMID:
29035617
7.

Rare Gastric Cardia Polyp Causing Complete Esophageal Obstruction.

Leroy K, Moy B, Rezaizadeh H.

ACG Case Rep J. 2017 Sep 27;4:e110. doi: 10.14309/crj.2017.110. eCollection 2017.

8.

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A.

J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223. doi: 10.6004/jnccn.2017.0158.

PMID:
28982747
9.

Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer
.

Post KE, Moy B, Furlani C, Strand E, Flanagan J, Peppercorn JM.

Clin J Oncol Nurs. 2017 Aug 1;21(4):E99-E105. doi: 10.1188/17.CJON.E99-E105.

PMID:
28738044
10.

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.

Spring LM, Zangardi ML, Moy B, Bardia A.

Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Review.

11.

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH.

J Clin Oncol. 2017 Jun 20;35(18):2062-2081. doi: 10.1200/JCO.2016.70.7257. Epub 2017 Mar 6. Review.

PMID:
28618241
12.

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS.

Breast Cancer Res Treat. 2017 Jun;163(3):535-544. doi: 10.1007/s10549-017-4199-3. Epub 2017 Mar 21.

PMID:
28324268
13.

Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).

Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA.

Biomed Opt Express. 2017 Jan 4;8(2):555-569. doi: 10.1364/BOE.8.000555. eCollection 2017 Feb 1.

14.

Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011.

Chavarri-Guerra Y, St Louis J, Bukowski A, Soto-Perez-de-Celis E, Liedke PER, Symecko H, Moy B, Higgins M, Finkelstein DM, Goss PE.

Breast. 2017 Feb;31:197-201. doi: 10.1016/j.breast.2016.11.014. Epub 2016 Nov 25.

PMID:
27894048
15.

The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?

Jackson JD, Moy B, Evans MK.

Oncologist. 2016 Dec;21(12):1411-1413. Epub 2016 Nov 7. No abstract available.

16.

No Conflict, No Interest.

Nipp RD, Moy B.

JAMA Oncol. 2016 Dec 1;2(12):1631-1632. doi: 10.1001/jamaoncol.2016.2726. No abstract available.

PMID:
27560041
17.

Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.

Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA.

J Natl Cancer Inst. 2016 Jul 7;108(12). pii: djw163. doi: 10.1093/jnci/djw163. Print 2016 Dec.

18.

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A.

JAMA Oncol. 2016 Nov 1;2(11):1477-1486. doi: 10.1001/jamaoncol.2016.1897. Review.

19.

Primary Follicular Lymphoma of the Gastrointestinal Tract: Case Report and Review.

Moy BT, Wilmot J, Ballesteros E, Forouhar F, Vaziri H.

J Gastrointest Cancer. 2016 Sep;47(3):255-63. doi: 10.1007/s12029-016-9847-z. Review.

PMID:
27277664
20.

Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications.

Melisko ME, Gradishar WJ, Moy B.

Am Soc Clin Oncol Educ Book. 2016;35:e22-9. doi: 10.14694/EDBK_159203. Review.

21.

Gastric Diverticulum: An Unusual Endoscopic Finding.

Moy BT, Marchioni Beery RM, Birk JW.

ACG Case Rep J. 2016 Apr 15;3(3):150-1. doi: 10.14309/crj.2016.31. eCollection 2016 Apr. No abstract available.

22.

Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.

Nipp RD, Lee H, Powell E, Birrer NE, Poles E, Finkelstein D, Winkfield K, Percac-Lima S, Chabner B, Moy B.

Oncologist. 2016 Apr;21(4):467-74. doi: 10.1634/theoncologist.2015-0481. Epub 2016 Mar 14.

23.

Probable doxycycline-induced acute pancreatitis.

Moy BT, Kapila N.

Am J Health Syst Pharm. 2016 Mar 1;73(5):286-91. doi: 10.2146/ajhp150298.

PMID:
26896500
24.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group.

Lancet Oncol. 2016 Mar;17(3):367-77. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.

PMID:
26874901
25.

Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers.

Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU.

Breast Cancer Res Treat. 2016 Feb;155(3):569-78. doi: 10.1007/s10549-016-3707-1. Epub 2016 Feb 11.

PMID:
26868124
26.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

27.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
28.

Announcing a New Journal Section: Community Outreach.

Evans M, Moy B.

Oncologist. 2016 Jan;21(1):1. doi: 10.1634/theoncologist.2015-0494. Epub 2015 Dec 28. No abstract available.

29.

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM.

JAMA Oncol. 2016 Jan;2(1):29-36. doi: 10.1001/jamaoncol.2015.3709.

30.

Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.

Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R, Blitzblau RC, Moy B, Breslin T, Edge SB, Hassett MJ, Punglia RS.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):622-30. doi: 10.1016/j.ijrobp.2015.07.006. Epub 2015 Jul 11.

PMID:
26461004
31.

Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.

Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A.

J Clin Oncol. 2015 Nov 1;33(31):3621-7. doi: 10.1200/JCO.2015.62.2126. Epub 2015 Sep 14.

32.

An Update to Hepatobiliary Stents.

Moy BT, Birk JW.

J Clin Transl Hepatol. 2015 Mar;3(1):67-77. doi: 10.14218/JCTH.2015.00040. Epub 2015 Mar 15. Review.

33.

Azithromycin-Induced Cholestatic Hepatitis.

Moy BT, Dojki FK, Scholes JV, Hoffman MG.

Conn Med. 2015 Apr;79(4):213-5. Review. No abstract available.

PMID:
26259299
34.

The impact of industry on oncology research and practice.

Moy B, Jagsi R, Gaynor RB, Ratain MJ.

Am Soc Clin Oncol Educ Book. 2015:130-7. doi: 10.14694/EdBook_AM.2015.35.130. Review.

35.

Recognizing the Financial Burden of Cancer Patients in Clinical Trials.

Nipp RD, Powell E, Chabner B, Moy B.

Oncologist. 2015 Jun;20(6):572-5. doi: 10.1634/theoncologist.2015-0068. Epub 2015 May 18. No abstract available.

36.

Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene.

Moy B.

Oncologist. 2015 Jun;20(6):571. doi: 10.1634/theoncologist.2015-0137. Epub 2015 May 18. No abstract available.

37.

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM.

Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16.

38.

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Breast Cancer Res. 2015 Apr 16;17:56. doi: 10.1186/s13058-015-0568-1.

39.

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.

Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU.

Cancer. 2015 Jun 15;121(12):1937-48. doi: 10.1002/cncr.29310. Epub 2015 Mar 10.

40.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators.

Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.

PMID:
25752740
41.

Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.

Moy B, Specht MC, Lanuti M, Rafferty EA, Lerwill MF.

N Engl J Med. 2015 Jan 8;372(2):162-70. doi: 10.1056/NEJMcpc1408601. No abstract available.

PMID:
25564900
42.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.

N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. Erratum in: N Engl J Med. 2015 Nov 12;373(20):1989.

43.

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE.

J Clin Oncol. 2015 Feb 1;33(4):340-8. doi: 10.1200/JCO.2013.54.6119. Epub 2014 Dec 22. Erratum in: J Clin Oncol. 2015 Apr 1;33(10):1227.

44.

American Society of Clinical Oncology policy statement on medicaid reform.

Polite BN, Griggs JJ, Moy B, Lathan C, duPont NC, Villani G, Wong SL, Halpern MT.

J Clin Oncol. 2014 Dec 20;32(36):4162-7. doi: 10.1200/JCO.2014.56.3452. Epub 2014 Nov 17. No abstract available.

45.

Debating the oncologist's role in defining the value of cancer care: our duty is to our patients.

Sulmasy D, Moy B.

J Clin Oncol. 2014 Dec 20;32(36):4039-41. doi: 10.1200/JCO.2014.57.8716. Epub 2014 Nov 3. No abstract available.

PMID:
25366686
46.

Gene deletions in Mycobacterium bovis BCG stimulate increased CD8+ T cell responses.

Panas MW, Sixsmith JD, White K, Korioth-Schmitz B, Shields ST, Moy BT, Lee S, Schmitz JE, Jacobs WR Jr, Porcelli SA, Haynes BF, Letvin NL, Gillard GO.

Infect Immun. 2014 Dec;82(12):5317-26. doi: 10.1128/IAI.02100-14. Epub 2014 Oct 6.

47.

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE.

J Clin Oncol. 2014 Oct 10;32(29):3307-29. doi: 10.1200/JCO.2014.56.7479. Epub 2014 Sep 2.

PMID:
25185096
48.

Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.

Lee CN, Wetschler MH, Chang Y, Belkora JK, Moy B, Partridge A, Sepucha KR.

BMC Med Inform Decis Mak. 2014 Aug 20;14:73. doi: 10.1186/1472-6947-14-73.

49.

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU.

J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2.

50.

Value of cancer care: ethical considerations for the practicing oncologist.

Jagsi R, Sulmasy DP, Moy B.

Am Soc Clin Oncol Educ Book. 2014:e146-9. doi: 10.14694/EdBook_AM.2014.34.e146. Review.

Supplemental Content

Support Center